Leaders and Experts from Microsoft, AWS, Google, Fervo, AIQ and Commonwealth Fusion Headline Innovation and Technology Programming at CERAWeek by S&P Global
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2025
0mins
Should l Buy SPGI?
Source: PRnewswire
CERAWeek 2025 Overview: The upcoming CERAWeek by S&P Global, scheduled for March 10-14 in Houston, will focus on technology, innovation, and decarbonization, featuring leaders from major tech companies and over 250 startups showcasing advancements in energy and related fields.
Innovation Agora Programming: The conference will include various interactive sessions such as the "Voices of Innovation," Energy Venture Day, and new initiatives like the NexGen program aimed at connecting academia with industry to foster talent and innovation in the energy sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SPGI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SPGI
Wall Street analysts forecast SPGI stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 433.190
Low
546.00
Averages
617.77
High
675.00
Current: 433.190
Low
546.00
Averages
617.77
High
675.00
About SPGI
S&P Global Inc. provides essential intelligence. Its operations consist of five businesses: S&P Global Market Intelligence (Market Intelligence), S&P Global Ratings (Ratings), S&P Global Commodity Insights (Commodity Insights), S&P Global Mobility (Mobility) and S&P Dow Jones Indices (Indices). Market Intelligence is a global provider of multi-asset-class data and analytics integrated with purpose-built workflow solutions. Ratings is an independent provider of credit ratings, research, and analytics, offering investors and other market participants information, ratings and benchmarks. Commodity Insights is an independent provider of information and benchmark prices for the commodity and energy markets. Mobility is a provider of solutions serving the full automotive value chain, including vehicle manufacturers and retailers. Indices is a global index provider that maintains a variety of valuation and index benchmarks for investment advisors, wealth managers and institutional investors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
S&P Global Q1 2026 Earnings Call Insights
- Significant Revenue Growth: S&P Global reported a 10% year-over-year revenue increase in Q1 2026, with a 9% rise on an organic constant currency basis, indicating sustained competitiveness in the market and providing funding for future investments and expansions.
- Shareholder Return Plan: The company returned $1 billion to shareholders through share repurchases, raising the expected repurchase amount from 85% to at least 100% of adjusted free cash flow, which not only boosts shareholder confidence but also reflects optimism about future cash flows.
- Energy Market Challenges: The conflict in Iran has caused significant disruptions in the energy market, with management cautioning that it may take time for supply chains to normalize, potentially impacting growth in the energy sector and highlighting macroeconomic uncertainties.
- Software Business Divestiture: The company has signed an agreement to divest its upstream software portfolio, expected to close in the second half of 2026 or early 2027, a strategic move aimed at optimizing resource allocation and focusing on core operations to enhance overall efficiency.
See More
Veeva Systems to Replace Coterra Energy in S&P 500 Effective May 7, 2026
- Index Change: Veeva Systems will replace Coterra Energy in the S&P 500 effective May 7, 2026, indicating a shift in market focus towards the healthcare sector, which may enhance Veeva's market visibility.
- Acquisition Deal: Devon Energy is acquiring Coterra Energy, with the deal expected to close soon, which will further consolidate resources in the energy sector and could impact stock performance of related companies.
- Market Impact: This index change is likely to attract more investor attention to Veeva Systems, particularly in the healthcare space, potentially increasing its liquidity and market share.
- Index Significance: As one of the most influential stock indices globally, changes in the S&P 500 typically garner widespread market attention, reflecting investor expectations regarding industry trends.
See More
Veeva Systems to Replace Coterra Energy in S&P 500
- S&P 500 Change: Veeva Systems will replace Coterra Energy in the S&P 500 effective May 7, 2026, which is expected to enhance Veeva's visibility and attract investor interest in the market.
- Acquisition Dynamics: Devon Energy is acquiring Coterra Energy, with the deal expected to close soon, further consolidating resources in the energy sector and potentially impacting the stock performance of related companies.
- Industry Impact Analysis: Veeva's inclusion in the S&P 500 will strengthen its influence in the healthcare sector, likely attracting more institutional investors and driving its stock price upward.
- Market Reaction Expectations: The exit of Coterra Energy may cause short-term volatility in the energy sector, while Veeva's entry could create new investment opportunities in the healthcare industry.
See More
VEEVA SYSTEMS TO BE ADDED TO S&P 500 INDEX
Veeva Systems Joins S&P 500: Veeva Systems has been added to the S&P 500 index, reflecting its growth and significance in the market.
Impact on Market: The inclusion of Veeva in the S&P 500 is expected to influence investor sentiment and potentially increase its stock value.
See More
Blackstone's $400 Million Investment in Teva: A Strategic Bet
- Investment Scale and Strategic Significance: Blackstone Life Sciences' $400 million investment in Teva Pharmaceuticals in March 2023 reflects strong confidence in the new drug duvakitug, representing not just financial backing but a significant bet on Teva's future development.
- Drug Potential and Clinical Progress: Duvakitug, a monoclonal antibody targeting TL1A, is currently undergoing Phase 3 clinical trials for ulcerative colitis and Crohn's disease, with promising Phase 2 results showing durable efficacy over 44 weeks, indicating a broad market potential.
- Teva's Transformation and Market Recognition: Teva has evolved from a mere generic drug manufacturer to a leader in biopharmaceutical innovation, with credit rating agencies upgrading its rating to BB+, reflecting market confidence in its transformation.
- Opportunities and Risks for Investors: Blackstone's investment not only provides Teva with financial support but may also yield milestone payments and low single-digit royalties on global sales, suggesting that while risk-averse investors might hesitate, aggressive investors could find significant value in Teva, especially if duvakitug succeeds as anticipated.
See More
Blackstone Commits $400 Million to Teva's Drug Development
- Significant Investment: Blackstone Life Sciences has committed $400 million to Teva Pharmaceuticals to support the development of its autoimmune disease drug, duvakitug, reflecting confidence in Teva's future and showcasing Blackstone's strategic positioning in the biopharmaceutical sector.
- Clinical Trial Progress: Duvakitug is currently undergoing Phase 3 clinical trials aimed at treating ulcerative colitis and Crohn's disease, with promising Phase 2 results indicating durable efficacy over 44 weeks, suggesting substantial market potential and the possibility of becoming a best-in-class therapy.
- Credit Rating Upgrade: Following Blackstone's investment, credit rating agencies have begun to recognize Teva's turnaround, with S&P Global upgrading Teva's credit rating from BB to BB+ in December 2025, reflecting a stable outlook and market optimism about its future development.
- Positive Market Outlook: Analysts are generally bullish on Teva, with 12 out of 13 surveyed analysts rating the stock as a
See More
S&P Global Q1 2026 Earnings Call Insights
- Significant Revenue Growth: S&P Global reported a 10% year-over-year revenue increase in Q1 2026, with a 9% rise on an organic constant currency basis, indicating sustained competitiveness in the market and providing funding for future investments and expansions.
- Shareholder Return Plan: The company returned $1 billion to shareholders through share repurchases, raising the expected repurchase amount from 85% to at least 100% of adjusted free cash flow, which not only boosts shareholder confidence but also reflects optimism about future cash flows.
- Energy Market Challenges: The conflict in Iran has caused significant disruptions in the energy market, with management cautioning that it may take time for supply chains to normalize, potentially impacting growth in the energy sector and highlighting macroeconomic uncertainties.
- Software Business Divestiture: The company has signed an agreement to divest its upstream software portfolio, expected to close in the second half of 2026 or early 2027, a strategic move aimed at optimizing resource allocation and focusing on core operations to enhance overall efficiency.
See More
Veeva Systems to Replace Coterra Energy in S&P 500 Effective May 7, 2026
- Index Change: Veeva Systems will replace Coterra Energy in the S&P 500 effective May 7, 2026, indicating a shift in market focus towards the healthcare sector, which may enhance Veeva's market visibility.
- Acquisition Deal: Devon Energy is acquiring Coterra Energy, with the deal expected to close soon, which will further consolidate resources in the energy sector and could impact stock performance of related companies.
- Market Impact: This index change is likely to attract more investor attention to Veeva Systems, particularly in the healthcare space, potentially increasing its liquidity and market share.
- Index Significance: As one of the most influential stock indices globally, changes in the S&P 500 typically garner widespread market attention, reflecting investor expectations regarding industry trends.
See More
Veeva Systems to Replace Coterra Energy in S&P 500
- S&P 500 Change: Veeva Systems will replace Coterra Energy in the S&P 500 effective May 7, 2026, which is expected to enhance Veeva's visibility and attract investor interest in the market.
- Acquisition Dynamics: Devon Energy is acquiring Coterra Energy, with the deal expected to close soon, further consolidating resources in the energy sector and potentially impacting the stock performance of related companies.
- Industry Impact Analysis: Veeva's inclusion in the S&P 500 will strengthen its influence in the healthcare sector, likely attracting more institutional investors and driving its stock price upward.
- Market Reaction Expectations: The exit of Coterra Energy may cause short-term volatility in the energy sector, while Veeva's entry could create new investment opportunities in the healthcare industry.
See More
VEEVA SYSTEMS TO BE ADDED TO S&P 500 INDEX
Veeva Systems Joins S&P 500: Veeva Systems has been added to the S&P 500 index, reflecting its growth and significance in the market.
Impact on Market: The inclusion of Veeva in the S&P 500 is expected to influence investor sentiment and potentially increase its stock value.
See More
Blackstone's $400 Million Investment in Teva: A Strategic Bet
- Investment Scale and Strategic Significance: Blackstone Life Sciences' $400 million investment in Teva Pharmaceuticals in March 2023 reflects strong confidence in the new drug duvakitug, representing not just financial backing but a significant bet on Teva's future development.
- Drug Potential and Clinical Progress: Duvakitug, a monoclonal antibody targeting TL1A, is currently undergoing Phase 3 clinical trials for ulcerative colitis and Crohn's disease, with promising Phase 2 results showing durable efficacy over 44 weeks, indicating a broad market potential.
- Teva's Transformation and Market Recognition: Teva has evolved from a mere generic drug manufacturer to a leader in biopharmaceutical innovation, with credit rating agencies upgrading its rating to BB+, reflecting market confidence in its transformation.
- Opportunities and Risks for Investors: Blackstone's investment not only provides Teva with financial support but may also yield milestone payments and low single-digit royalties on global sales, suggesting that while risk-averse investors might hesitate, aggressive investors could find significant value in Teva, especially if duvakitug succeeds as anticipated.
See More
Blackstone Commits $400 Million to Teva's Drug Development
- Significant Investment: Blackstone Life Sciences has committed $400 million to Teva Pharmaceuticals to support the development of its autoimmune disease drug, duvakitug, reflecting confidence in Teva's future and showcasing Blackstone's strategic positioning in the biopharmaceutical sector.
- Clinical Trial Progress: Duvakitug is currently undergoing Phase 3 clinical trials aimed at treating ulcerative colitis and Crohn's disease, with promising Phase 2 results indicating durable efficacy over 44 weeks, suggesting substantial market potential and the possibility of becoming a best-in-class therapy.
- Credit Rating Upgrade: Following Blackstone's investment, credit rating agencies have begun to recognize Teva's turnaround, with S&P Global upgrading Teva's credit rating from BB to BB+ in December 2025, reflecting a stable outlook and market optimism about its future development.
- Positive Market Outlook: Analysts are generally bullish on Teva, with 12 out of 13 surveyed analysts rating the stock as a
See More
